NAUT News & Events

Nautilus Biotechnology announced the appointment of Amber Faust as Vice President of Sales. Faust joins Nautilus following the public debut of the Nautilus Voyager Platform.

"In Q4, Nautilus maintained disciplined execution and delivered meaningful progress across our platform development, strategic collaborations, and early commercial engagement aligned with our path toward commercialization in late 2026," said Sujal Patel, CEO of Nautilus Biotechnology. "Our near-term focus remains on the successful expansion of our Early Access Program, beginning with Tau proteoforms and broadening over time, while continuing to advance our broadscale capabilities. These milestones are important steps toward enabling customers to experience the value of our technology and progressing toward full commercial availability."

Nautilus Biotechnology debuted the Voyager Platform, which is designed to power the Iterative Mapping of up to 10 billion intact proteins and proteoforms simultaneously in a single run. "We're excited to bring our vision of democratizing access to proteomics to fruition and share the Voyager Platform first with researchers seeking deeper insight into protein biology," said Parag Mallick, Ph.D., Co-Founder and Chief Scientist of Nautilus. "After years of intensive development, Voyager is designed to be a benchtop tool that can help advance biomarker discovery, diagnostics, and therapeutic innovation."